Literature DB >> 19578595

Impact of abdominal fat and insulin resistance on arterial hypertension in non-obese women.

Eliana A Silva1, Fernando Flexa, Maria Teresa Zanella.   

Abstract

OBJECTIVE: To evaluate the impact of abdominal fat and insulin resistance on arterial hypertension of non-obese women.
METHODS: Thirty-five non-obese women (NO), age 35-68 years were studied, and divided into two groups according to the presence of hypertension (BP >or= 140 x 90 mmHg) (HT = hypertensive; NT = normotensive). Leptin measurement and oral glucose tolerance test (OGTT) to assess insulin were performed in these patients. A CT-scan was used to evaluate visceral (VF) and subcutaneous abdominal fat (SCF). The Central fat distribution index (CDI) was proposed to evaluate the impact of subcutaneous abdominal fat on central fat distribution in hypertensive patients.
RESULTS: When compared to NT-NO (n = 17) group, HT-NO (n = 18) showed higher blood pressure levels (systolic and diastolic), greater VF area (84.40 +/- 55.70 versus 37.50 +/- 23.00 cm(2); p = 0.036), greater SCF area (174.30 +/- 83.00 versus 79.80 +/- 27.40 cm(2); p = 0.030), higher HOMAr index (1.59 +/- 0.72 versus 0.93 +/- 0.48 mmol*mU/L(2); p = 0.006), higher CDI index (12.67 +/- 7.04 versus 6.19 +/- 2.57 cm(2)/kg) and higher leptin level (19.1 +/- 9.6 versus 7.4 +/- 3.5 ng/mL; p = 0.028).
CONCLUSIONS: Arterial hypertension in non-obese women is associated with insulin resistance, central fat distribution and higher leptin levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578595     DOI: 10.1590/s0004-27302009000300007

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  10 in total

Review 1.  A review of cardiopulmonary research in Brazilian medical journals: clinical, surgical and epidemiological data.

Authors:  Carlos Serrano; Mauricio Rocha e Silva
Journal:  Clinics (Sao Paulo)       Date:  2010-04       Impact factor: 2.365

Review 2.  Metabolic and infectious pathologies in Brazilian medical literature: a review.

Authors:  Mauricio Rocha-e-Silva
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

3.  The Relationship of Residual Renal Function with Cardiovascular Morbidity in Hemodialysis Patients and the Potential Role of Monocyte Chemoattractant Protein-1.

Authors:  Vaia D Raikou; Vasilios Kardalinos; Despina Kyriaki
Journal:  Kidney Dis (Basel)       Date:  2017-11-17

Review 4.  Adipokines: novel players in resistant hypertension.

Authors:  Ana Paula de Faria; Rodrigo Modolo; Vanessa Fontana; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-09-04       Impact factor: 3.738

5.  The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment.

Authors:  Vaia D Raikou; Despina Kyriaki
Journal:  J Diabetes Metab Disord       Date:  2015-04-23

6.  Importance of serum phosphate in elderly patients with diabetes mellitus.

Authors:  Vaia D Raikou; Despina Kyriaki; Sotiris Gavriil
Journal:  World J Diabetes       Date:  2020-10-15

Review 7.  Visceral Adipose Tissue Influence on Health Problem Development and Its Relationship with Serum Biochemical Parameters in Middle-Aged and Older Adults: A Literature Review.

Authors:  Vanessa C Moreira; Calliandra M S Silva; Alexis F Welker; Izabel C R da Silva
Journal:  J Aging Res       Date:  2022-04-19

8.  Glucose Serum Concentrations and Cardiovascular Disease in Patients on the End Stage of Renal Disease without Diabetes Mellitus.

Authors:  Vaia D Raikou; Despina Kyriaki
Journal:  J Cardiovasc Dev Dis       Date:  2015-04-24

9.  Mortality and Low Serum Bicarbonate Level in Patients on Hemodiafiltration versus Peritoneal Dialysis.

Authors:  V D Raikou; D Kyriaki
Journal:  Indian J Nephrol       Date:  2018 Mar-Apr

10.  Oxidized Low-Density Lipoprotein Serum Concentrations and Cardiovascular Morbidity in End Stage of Renal Disease.

Authors:  Vaia Raikou; Vasilios Kardalinos; Despina Kyriaki
Journal:  J Cardiovasc Dev Dis       Date:  2018-06-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.